Quantcast
Last updated on April 18, 2014 at 17:24 EDT

Latest misoprostol Stories

2013-05-02 08:38:08

Pivotal data for investigational controlled release misoprostol vaginal insert in the U.S. accepted for presentation NEW ORLEANS, May 2, 2013 /PRNewswire/ -- Ferring Pharmaceuticals will present efficacy and safety data from its Phase 3 EXPEDITE* study for its investigational controlled release misoprostol vaginal insert (MVI) at the 61(st) annual clinical meeting of the American College of Obstetricians and Gynecologists in New Orleans, May 4 - 8, 2013. Studies accepted for...

2013-02-12 08:30:08

SAN FRANCISCO, Feb. 12, 2013 /PRNewswire/ -- Ferring Pharmaceuticals will present pivotal Phase 3 efficacy and safety data from its EXPEDITE* study for its investigational controlled release misoprostol vaginal insert (MVI) at the 33(rd) annual meeting of the Society for Maternal-Fetal Medicine (SMFM) in San Francisco, February 11 - 16. These and other research findings formed the basis for Ferring's New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) supporting the use...

2012-10-23 11:24:41

PARSIPPANY, N.J., Oct. 23, 2012 /PRNewswire/ -- Ferring Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for its controlled release misoprostol vaginal insert (MVI). Ferring is seeking approval for the MVI for decreasing time to vaginal delivery in women with an unfavorable cervix (a cervix that has not yet softened and thinned so that dilation can take place) when used in sequential regimen with...

2012-10-10 07:28:49

ROME, October 10, 2012 /PRNewswire/ -- "Many preventable deaths occur during pregnancy and childbirth in the developing world where maternal mortality ranges from 200 to 2,000 per 100,000 live births. Moreover, for each woman who dies, an estimated 16 to 30 survive avoidable complications, often miserably," said Professor Gamal Serour, President of the International Federation of Gynecology and Obstetrics (FIGO), presenting the most recent Initiatives for the prevention and...

2012-04-16 13:08:31

Increases risk of upper GI complications To relieve pain, arthritis sufferers are prescribed medications that may include non-steroidal anti-inflammatory drugs (NSAIDs) or cyclooxygenase-2 (COX-2) inhibitors, both of which can irritate the digestive tract. At times additional drugs are co-prescribed with NSAIDs or COX-2 inhibitors to prevent adverse gastrointestinal (GI) effects. Now a new study available today in the American College of Rheumatology journal, Arthritis & Rheumatism,...

2010-07-07 16:55:11

Molecular research shows misoprostol prevents cell communication A York University study has shown for the first time how the drug misoprostol, which has been linked to neurodevelopmental defects associated with autism, interferes with neuronal cell function. It is an important finding because misoprostol is similar in structure to naturally-occurring prostaglandins, which are the key signaling molecules produced by fatty acids in the brain. Past clinical studies have shown an association...

2010-06-15 07:00:00

KING OF PRUSSIA, Pa., June 15 /PRNewswire/ -- Cytokine PharmaSciences, Inc. today announced the completion of a Phase II study of the misoprostol vaginal insert (MVI), a proprietary, controlled-release and retrievable polymer chip containing prostaglandin E(1) (PGE1). Results of the dose-finding study in pregnant women at term gestation confirm the efficacy and safety of this investigational product and suggest that the MVI may reduce time to delivery after induction, support more natural...

000e9e3d274ce8cc38c3e9d57879dd7c
2010-03-09 14:50:26

Swedish scientists are touting both the safety and effectiveness of home-based abortion medications for women who are 50 to 63 days pregnant, according to a March 9, 2010 Reuters report. Researchers at the Karolinska Institutet in Stockholm, led by Dr. Helena Kopp Kallner, state that this is the first survey to look at the use of the home-based procedure beyond 49 days post-conception. The procedure requires women to take a dose of mifepristone (also known as RU-486), followed three to four...

2009-11-18 14:40:39

Over 300 million patients use non-steroidal anti-inflammatory drugs (NSAIDs) in the world to treat pain, arthritis, fever and other diseases. Nearly 30% of the users suffer from gastric lesions and bleeding. To mitigate NSAIDs' adverse effects on the stomach, misoprostol, a non-selective prostaglandin E1 (PGE1) analogue, has been prescribed as the first choice for prevention of NSAID-induced injuries, but often induces severe adverse effects. There remain unmet medical needs for drugs with...

4e0ee6ce438c44680c6fd8573f8892271
2009-07-09 07:30:00

According to a study released this week by Planned Parenthood, approximately one out of every four American women who obtained an early abortion last year did so with the so-called "abortion pill" rather than through conventional surgery. Planned Parenthood, the world's largest international provider of reproductive health services, says the study shows that a new method of taking the pill has all but eliminated health risks that had been previously associated with the medication.  A...